|
|
|
20.04.26 - 08:01
|
Goldman sieht ernormes Potenzial bei Corvus - Anleger mit starken Nerven erwartet eine Verdopplungschance (Ariva)
|
|
|
Die Experten von Goldman Sachs trauen Corvus Pharmaceuticals mit Blick auf den Wirkstoff Soquelitinib einen kräftigen Kurssprung zu. Auch andere Analysten sehen weiteres Potenzial. Doch trotz der Euphorie bleibt die Biotech-Aktie eine hochspekulative Wette auf klinische Daten und den Erfolg in einem umkämpften Milliardenmarkt. Corvus Pharmaceuticals ist eines jener US-Biotechunternehmen, die lange unter dem Radar laufen und dann binnen weniger Monate plötzlich in den Fokus der Börse rücken. Das Unternehmen wurde 2014 gegründet, sitzt in South San Francisco und ist an der Nasdaq notiert. Operativ ......
|
|
|
20.04.26 - 07:00
|
Research: G Sachs Expects Hong Kong IPO Fundraising to Reach USD60B This Year (AAStocks)
|
|
|
Goldman Sachs said in a report that Hong Kong regained the top spot in the global equity financing market in 2025. Entering 2026, Hong Kong's IPO momentum has accelerated. So far this year, 40 companies have gone public, raising USD14 billion (YoY +488%).There are currently about 400 active applications, highlighting strong issu......
|
|
|
|
|
18.04.26 - 17:24
|
Goldman Sachs Kicks Off Earnings Season (Fool)
|
|
|
This episode covers financial results from Goldman Sachs, plus an update on the U.S. blockade in the Strait of Hormuz and a listener question regarding SpaceX's upcoming IPO....
|
|
|
18.04.26 - 00:06
|
Rosner on Credit Markets Amid Geopolitical Tension (Bloomberg)
|
|
|
Lindsay Rosner, Head of Multi Sector Fixed Income at Goldman Sachs Asset Management, discuss the current state of credit markets amid geopolitical tensions and private credit challenges. Rosner highlights that while credit spreads remain tight, the all-in yield remains attractive to investors. She speaks with Katie Greifeld on “Real Yield.” (Source: Bloomberg)...
|
|
|
17.04.26 - 22:14
|
′Permanent Scarring′ From Iran War: Goldman′s Rosner (Bloomberg)
|
|
|
Lindsay Rosner, head of multi-sector team at Goldman Sachs Asset Management, joins Katie Greifeld on "Bloomberg Real Yield." Credit investors who gambled on higher-yielding corporate bonds in the midst of the Iran war are looking increasingly vindicated as markets rebound as the Strait of Hormuz reopens. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
|
|
17.04.26 - 18:39
|
Goldman Sachs′ 2 Favorite Under-the-Radar Stocks (Benzinga)
|
|
|
Goldman Sachs calls Minimed Group a compelling play on the diabetes market and a potentially profitable stock, with a target price of $24. MiniMed produces insulin pump platforms and continuous glucose monitoring technologies, and recently gained FDA approval for its next-generation insulin pump. The global diabetes market is expected to grow significantly, making MiniMed a promising investment opportunity.
Importance Rank:
1
read more...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
